Pharmaceutical Giant Finalizes Acquisition of Obesity Drug Developer
Pfizer Adds Portfolio of Promising Cardiometabolic Treatment Candidates
The global pharmaceutical corporation Pfizer Inc. has announced the successful conclusion of its acquisition of the clinical-stage biotechnology firm, Metsera, Inc. This transaction formally establishes Metsera as a wholly owned subsidiary of Pfizer. Following the market close on the day of the acquisition, Metsera’s common stock ceased trading on the NASDAQ exchange.
Metsera specializes in the research and development of next-generation medicines targeting obesity and cardiometabolic diseases.
According to statements from Pfizer’s Chairman and Chief Executive Officer, the acquisition is a deliberate, strategic decision to invest resources into one of the most impactful and high-growth therapeutic areas in medicine’s future. The stated objective is to integrate Metsera’s innovative research pipeline with Pfizer’s global infrastructure for development, manufacturing, and commercialization, accelerating the delivery of promising therapies to patients worldwide.
The agreement adds a range of promising therapeutic candidates, strengthening Pfizer’s existing Internal Medicine pipeline. Notable candidates include:
-
MET-097i: A weekly or monthly injectable GLP-1 receptor agonist (RA), positioned to commence Phase 3 development.
-
MET-233i: A monthly amylin analog candidate, currently under evaluation in Phase 1 as both a monotherapy and in combination with MET-097i.
-
An oral GLP-1 RA candidate also in Phase 1 development.
-
Several preclinical nutrient-stimulated hormone therapeutics.
Pfizer paid $65.60 in cash for each outstanding share of Metsera’s common stock, valuing the enterprise at approximately $7.0 billion. Metsera shareholders are also eligible for up to an additional $20.65 per share via a Contingent Value Right (CVR), contingent upon the achievement of three specified clinical and regulatory milestones.
The company disclosed that the transaction is projected to be dilutive to earnings through 2030, primarily due to the necessary further investment in several late-stage pipeline candidates. An update to Pfizer’s financial outlook will be provided later this year, coinciding with the 2026 guidance release.
Source:Â https://www.businesswire.com/news/home/20251112938725/en/Pfizer-Completes-Acquisition-of-Metsera
